Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Zoetis Inc Cl A (ZTS)

Zoetis Inc Cl A (ZTS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 64,924,316
  • Shares Outstanding, K 476,299
  • Annual Sales, $ 5,825 M
  • Annual Income, $ 1,428 M
  • 60-Month Beta 0.81
  • Price/Sales 10.70
  • Price/Cash Flow 36.26
  • Price/Book 24.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.88
  • Number of Estimates 8
  • High Estimate 0.89
  • Low Estimate 0.87
  • Prior Year 0.79
  • Growth Rate Est. (year over year) +11.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
131.45 +3.70%
on 12/31/19
143.33 -4.90%
on 01/22/20
+3.39 (+2.55%)
since 12/24/19
3-Month
114.96 +18.57%
on 11/14/19
143.33 -4.90%
on 01/22/20
+13.36 (+10.87%)
since 10/24/19
52-Week
82.96 +64.31%
on 01/28/19
143.33 -4.90%
on 01/22/20
+52.65 (+62.93%)
since 01/24/19

Most Recent Stories

More News
Can Zoetis (ZTS) Keep the Earnings Surprise Streak Alive?

Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

ZTS : 136.31 (-1.47%)
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?

Style Box ETF report for DEF

DEF : 57.39 (-0.52%)
LLY : 139.07 (-1.52%)
LMT : 432.50 (+0.87%)
IWF : 183.25 (-0.90%)
QQQ : 222.70 (-0.84%)
ZTS : 136.31 (-1.47%)
Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2019 Financial Results

Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Feb. 13, 2020. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer...

ZTS : 136.31 (-1.47%)
JAZZ vs. ZTS: Which Stock Is the Better Value Option?

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

JAZZ : 145.74 (-2.25%)
ZTS : 136.31 (-1.47%)
The Zacks Analyst Blog Highlights: Texas Instruments, Charter, Lowe's, Caterpillar and Zoetis

The Zacks Analyst Blog Highlights: Texas Instruments, Charter, Lowe's, Caterpillar and Zoetis

LOW : 120.23 (-2.02%)
CHTR : 504.67 (-1.65%)
CAT : 140.38 (-1.66%)
ZTS : 136.31 (-1.47%)
TXN : 130.52 (-2.78%)
Top Analyst Reports for Texas Instruments, Charter & Lowe's

Top Analyst Reports for Texas Instruments, Charter & Lowe's

ZTS : 136.31 (-1.47%)
TXN : 130.52 (-2.78%)
LOW : 120.23 (-2.02%)
CHTR : 504.67 (-1.65%)
CAT : 140.38 (-1.66%)
BLK : 536.84 (-0.94%)
Zoetis to Participate in the 38th Annual J.P. Morgan Healthcare Conference

Zoetis Inc. (NYSE:ZTS) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2020, in San Francisco, Calif. Kristin Peck, who will become Chief Executive Officer of...

JPM : 133.15 (-2.48%)
ZTS : 136.31 (-1.47%)
JAZZ vs. ZTS: Which Stock Is the Better Value Option?

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

JAZZ : 145.74 (-2.25%)
ZTS : 136.31 (-1.47%)
Zoetis Surges 45.3% YTD on Strong Portfolio & New Approvals

Zoetis (ZTS) surges on strong performance year to date, backed by a solid portfolio and prudent acquisitions.

BAYRY : 20.8000 (-3.66%)
ZTS : 136.31 (-1.47%)
JAZZ : 145.74 (-2.25%)
ELAN : 31.57 (-2.11%)
Top Analyst Reports for Alibaba, Disney & Morgan Stanley

Top Analyst Reports for Alibaba, Disney & Morgan Stanley

ZTS : 136.31 (-1.47%)
MS : 54.55 (-1.76%)
HMC : 26.89 (-1.90%)
ENB : 41.05 (+0.12%)
DIS : 140.08 (-1.49%)
BABA : 213.75 (-2.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ZTS with:

Business Summary

Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.

See More

Key Turning Points

2nd Resistance Point 140.83
1st Resistance Point 138.57
Last Price 136.31
1st Support Level 135.10
2nd Support Level 133.89

See More

52-Week High 143.33
Last Price 136.31
Fibonacci 61.8% 120.27
Fibonacci 50% 113.15
Fibonacci 38.2% 106.02
52-Week Low 82.96

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar